Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome

American Journal of Veterinary Research

Volumn 67, Issue 4, 2006, Pages 557-561

  Symonds, Kelly D ^a,c   MacAllister, Charles G ^a   Erkert, Ronald S ^a   Payton, Mark E ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b 301 MSCS   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETODOLAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ANALGESIC ACTIVITY; ANALYSIS OF VARIANCE; ANALYTIC METHOD; ANIMAL LAMENESS; ARTICLE; BONE PAIN; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GROUND REACTION FORCE; HORSE; HORSE DISEASE; MALE; NONHUMAN; RANDOMIZATION; SCAPHOID BONE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; ANIMAL; ANIMAL DISEASE; FOOT DISEASE; SYNDROME; TARSAL BONE;

ANIMALIA; EQUIDAE; ZEA MAYS;

ANALGESIA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ETODOLAC; FEMALE; FOOT DISEASES; HORSE DISEASES; HORSES; MALE; SYNDROME; TARSAL BONES;

EID: 33646847671     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.4.557     Document Type: Article

References (36)

1. USDA. APHIS info sheet: national economic cost of equine lameness, colic, and equine protozoal myeloencephalitis (EPM) in the United States. Washington, DC: USDA, Animal and Plant Health Inspection Service, 2001.
2. McIlwraith CW, Frisbie DD, Kawcak CE. Nonsteroidal anti-inflammatory drugs, in Proceedings. 47th Annu Meet Am Assoc Equine Pract 2001;182-187.
3. Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study. J Am Vet Med Assoc 1984;184:699-703.
4. MacAllister CG, Morgan SJ, Borne AT, et al. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and keto-profen in horses. J Am Vet Med Assoc 1993;202:71-77.
5. Johnston SA, Fox SM. Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis. J Am Vet Med Assoc 1997;210:1486-1492.
6. Tomlinson JE, Blikslager AT. Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair. J Am Vet Med Assoc 2003;222:946-951.
7. Schnitzer TJ, Constantine G. Etodolac (Iodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl 1997;47:23-31.
8. Johnston SA, Budsberg SC. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract 1997;27:841-862.
9. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-111.
10. Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810-818.
11. Campbell NB, Blikslager AT. The role of cyclooxygenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse. Equine Vet J Suppl 2000;32:59-64.
12. Campbell NB, Jones SL, Blikslager AT. The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon. Equine Vet J 2002;34:493-498.
13. Van Hoogmoed LM, Snyder JR, Harmon FA. In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon. Am J Vet Res 2002;63:1496-1500.
14. Morton AJ, Campbell NB, Gayle JM, et al. Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Res Vet Sci 2005;78:189-192.
15. Stashak T. Navicular syndrome (navicular disease). In: White NA, Moore JN, eds. Current techniques in equine surgery and lameness. 2nd ed. Philadelphia: WB Saunders Co, 1998;537-544.
16. Keegan KG, Wilson DA, Wilson DJ, et al. Evaluation of mild lameness in horses trotting on a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic gait analysis. Am J Vet Res 1998;59:1370-1377.
17. Barr ARS, Dow SM, Goodship AE. Parameters of forelimb ground reaction force in 48 normal ponies. Vet Rec 1995;136:283-286.
18. McLaughlin RM, Gaughan EM, Roush JK, et al. Effects of subject velocity on ground reaction force measurements and stance times in clinically normal horses at the walk and trot. Am J Vet Res 1996;57:7-11.
19. Merkens HW, Schamhardt HC. Evaluation of equine locomotion during different degrees of experimentally induced lameness. I: lameness model and quantification of ground reaction force patterns of the limbs. Equine Vet J Suppl 1988;6:99-106.
20. Merkens HW, Schamhardt HC. Evaluation of equine locomotion during different degrees of experimentally induced lameness. II: Distribution of ground reaction force patterns of concurrently loaded limbs. Equine Vet J Suppl 1988;6:107-112.
21. Merkens HW, Schamhardt HC, van Osch GJVM, et al. Ground reaction force patterns of Dutch Warmblood horses at normal trot. Equine Vet J 1993;25:134-137.
22. Merkens HW, Schamhardt HC, van Osch GJVM, et al. Ground reaction force patterns of Dutch Warmbloods at the canter. Am J Vet Res 1993;54:670-674.
23. Morris EA, Seeherman HJ. Redistribution of ground reaction forces in experimentally induced equine carpal lameness. Equine Exerc Physiol 1987;2:553-563.
24. Schamhardt HC, Merkens HW. Quantification of equine ground reaction force patterns. J Biomech 1987;20:443-446.
25. Erkert RS, MacAllister CG, Payton ME, et al. Use of force plate analysis to compare the analgesic effects of intravenous administration of phenylbutazone and flunixin meglumine in horses with navicular syndrome. Am J Vet Res 2005;66:284-288.
26. Hu HH, MacAllister CG, Payton ME, et al. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness. J Am Vet Med Assoc 2005;226:414-417.
27. MacAllister CG. Force plate analysis for the evaluation of NSAIDs in chronically lame horses, in Proceedings. 21st Annu Forum Am Coll Vet Intern Med 2003;162-163.
28. Blikslager AT, Campbell NB, Morton AJ. Alternative COX-2 inhibitors for management of pain in horses, in Proceedings. 20th Annu Forum Am Coll Vet Intern Med 2002;214-216.
29. American Association of Equine Practitioners. Definition and classification of lameness. In: Guide for veterinary service and judging of equestrian events. 4th ed. Lexington, Ky: American Association of Equine Practitioners, 1991;19.
30. 2 production in equine inflammation. Res Vet Sci 1984;37:347-349.
31. Lees P, Taylor JB, Maitho TE, et al. Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. Cornell Vet 1987;77:192-211.
32. Toutain PL, Autefage A, Legrand C, et al. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modeling. J Vet Pharmacol Ther 1994;17:459-469.
33. Giuliano F, Ferraz JG, Pereira R, et al. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 2001;426:95-103.
34. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998;59:1441-1446.
35. Koupai-Abyazani MR, Esaw B, Laviolette B. Etodolac in equine urine and serum: determination by high-performance liquid chromatography with ultraviolet detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry. J Anal Toxicol 1999;23:200-209.
36. Tomlinson JE, Wilder BO, Young KM, et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004;65:761-769.